stockrow
Saturday 7 November 2026
Export LYCA’s income statement to Excel — free account
Lycia Therapeutics Inc.
LYCA Healthcare Biotechnology
30.50
1.70
+5.90%
Follow LYCA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Lycia Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| STOK Stoke Therapeutics, Inc. | $1.7B | — (loss-making) | — (loss-making) | +5.86% (above 0%: growing) | n/m | −114.89% (below 0%: shrinking) | 100.00% | (686.94%) | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $1.7B | — (loss-making) | — (loss-making) | +330.01% (above 0%: growing) | n/m | +32.64% (above 0%: growing) | 95.44% | (139.32%) | Compare |
| ZBIO Zenas BioPharma, Inc. | $1.7B | — (loss-making) | — (loss-making) | — | n/m | −41.00% (below 0%: shrinking) | 100.00% | (1,034.09%) | Compare |
| LYCA Lycia Therapeutics Inc. | $1.7B | — | — | — | — | — | — | — | |
| NRIX Nurix Therapeutics, Inc. | $1.6B | 6.1× | 5.5× | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| ABSI Absci Corporation | $1.6B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| GENB Generate Biomedicines, Inc. | $1.6B | — (loss-making) | — (loss-making) | — | n/m | −224.24% (below 0%: shrinking) | 100.00% | (1,134.21%) | Compare |
| NVAX Novavax, Inc. | $1.6B | — (loss-making) | 110× | −3.05% (below 0%: shrinking) | n/m | −189.09% (below 0%: shrinking) | 65.61% | (45.80%) | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $1.6B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.6B | — | — | +1.41% | — | −56.37% | 100.00% | (413.13%) |